THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.13] ID: TIP-MED-000141

Fluconazole

Active Ingredient / Scientific Identity: Fluconazole • Class: Triazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Sterol Demethylase [CYP51] Inhibitor)

⚖️ Compare Profile
Generic / Entity NameFluconazole ([8.13])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassTriazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Sterol Demethylase [CYP51] I
Available Dosage FormsOral Uncoated / Dispersible Tablets & Capsules: 50 mg, 150 mg, 200 mg, 400 mg; IV Infusion: 200 mg/100 mL; Oph
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Strictly renal-function dependent (excreted >80% unchanged in urine)! • For a single one-time 150 mg dose (vaginal can
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Fluconazole (TIP-MED-000141, Reference Code [8.13]) is classified under Antimicrobials — Systemic Antifungal Agents (Ch 08) as a Triazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Sterol Demethylase [CYP51] Inhibitor). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.13], p. 99): Forcan (Cipla), Zocon (FDC Ltd), Fluka (Cipla), Syscan (Torrent), Onecan, AF-150 — Strengths & Dosage Forms: Oral Uncoated / Dispersible Tablets & Capsules: 50 mg, 150 mg, 200 mg, 400 mg; IV Infusion: 200 mg/100 mL; Ophthalmic Drops: 0.3% w/v
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.13], p. 99): Forcan (Cipla), Zocon (FDC Ltd), Fluka (Cipla), Syscan (Torrent), Onecan, AF-150 — Strengths & Dosage Forms: Oral Uncoated / Dispersible Tablets & Capsules: 50 mg, 150 mg, 200 mg, 400 mg; IV Infusion: 200 mg/100 mL; Ophthalmic Drops: 0.3% w/v
Dosage Forms & Available Strengths:
Oral Uncoated / Dispersible Tablets & Capsules: 50 mg, 150 mg, 200 mg, 400 mg; IV Infusion: 200 mg/100 mL; Ophthalmic Drops: 0.3% w/v
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Triazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Sterol Demethylase [CYP51] Inhibitor) acting on target receptor/enzyme pathways in Antimicrobials — Systemic Antifungal Agents (Ch 08): clinical efficacy is mediated via Triazole Systemic Antifungal (Fungal Cytochrome P450 14-Alpha-Sterol Demethylase [CYP51] Inhibitor) for Vulvovaginal candidiasis (single 150 mg oral dose); oropharyngeal and oesophageal candidiasis (e.g., steroid-inhaler thrush, immunocompromised); dermatophytosis (tinea corporis/cruris/pedis—150 mg once weekly for 4–6 weeks, though itraconazole/terbinafine are often preferred in recalcitrant Indian dermatophytosis) and tinea versicolor (400 mg single dose or 150–300 mg weekly); candiduria; cryptococcal meningitis..

4. Therapeutic Indications & Evidence-Supported Uses

  • Vulvovaginal candidiasis (single 150 mg oral dose)
  • oropharyngeal and oesophageal candidiasis (e
  • , steroid-inhaler thrush, immunocompromised)
  • dermatophytosis (tinea corporis/cruris/pedis—150 mg once weekly for 4–6 weeks, though itraconazole/terbinafine are often preferred in recalcitrant Indian dermatophytosis) and tinea versicolor (400 mg single dose or 150–300 mg weekly)
  • candiduria
  • cryptococcal meningitis

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Highly Indication-Specific! • Vulvovaginal Candidiasis: 150 mg as a single one-time dose (in severe or SGLT2-inhibitor-associated candidiasis, a second 150 mg dose 72 hours later is often prescribed). • Tinea / Onychomycosis: 150 mg once weekly. • Oropharyngeal Candidiasis: 200 mg Day 1, then 100 mg once daily for 7–14 days. Follow physician prescription.

Administration & Meal Timing: With or without food (unlike itraconazole capsules [which require food and gastric acid] or voriconazole [which requires an empty stomach], fluconazole is >90% water-soluble and absorbed completely regardless of food or PPIs!). | Any consistent time of day.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Strictly renal-function dependent (excreted >80% unchanged in urine)! • For a single one-time 150 mg dose (vaginal candidiasis), no renal dose adjustment is required. • For multiple-dose regimens when CrCl ≤50 mL/min (not on dialysis): Give the standard loading dose on Day 1, then reduce all subsequent maintenance doses by 50%! (After haemodialysis: give 100% of recommended dose post-session). Hepatic: Monitor LFTs closely in multi-dose therapy; discontinue if jaundice or clinical hepatitis develops.
Elimination & Renal Adjustment:
Renal: Strictly renal-function dependent (excreted >80% unchanged in urine)! • For a single one-time 150 mg dose (vaginal candidiasis), no renal dose adjustment is required. • For multiple-dose regimens when CrCl ≤50 mL/min (not on dialysis): Give the standard loading dose on Day 1, then reduce all subsequent maintenance doses by 50%! (After haemodialysis: give 100% of recommended dose post-session). Hepatic: Monitor LFTs closely in multi-dose therapy; discontinue if jaundice or clinical hepatitis develops.
Hepatic Impairment Considerations:
Renal: Strictly renal-function dependent (excreted >80% unchanged in urine)! • For a single one-time 150 mg dose (vaginal candidiasis), no renal dose adjustment is required. • For multiple-dose regimens when CrCl ≤50 mL/min (not on dialysis): Give the standard loading dose on Day 1, then reduce all subsequent maintenance doses by 50%! (After haemodialysis: give 100% of recommended dose post-session). Hepatic: Monitor LFTs closely in multi-dose therapy; discontinue if jaundice or clinical hepatitis develops.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated with co-administration of cisapride, terfenadine, astemizole, pimozide, quinidine, or erythromycin (fatal torsades de pointes!). Caution in QTc prolongation, hepatic dysfunction, renal impairment, and pregnancy (Category D in high or multi-dose regimens; even single 150 mg oral dose in 1st trimester is linked to increased spontaneous abortion—use topical Clotrimazole vaginal pessaries instead in pregnancy!).

Key Clinical Precautions: Renal: Strictly renal-function dependent (excreted >80% unchanged in urine)! • For a single one-time 150 mg dose (vaginal candidiasis), no renal dose adjustment is required. • For multiple-dose regimens when CrCl ≤50 mL/min (not on dialysis): Give the standard loading dose on Day 1, then reduce all subsequent maintenance doses by 50%! (After haemodialysis: give 100% of recommended dose post-session). Hepatic: Monitor LFTs closely in multi-dose therapy; discontinue if jaundice or clinical hepatitis develops.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nausea, abdominal pain, headache, mild diarrhoea, skin rash, transient hepatic transaminase elevation.
  • QTc interval prolongation and torsades de pointes, severe hepatotoxicity/hepatic necrosis (rare, mostly in patients with underlying severe medical illness), Stevens-Johnson Syndrome (SJS) / TEN, adrenal insufficiency (at high doses), alopecia (reversible, with prolonged therapy).
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • POTENT INHIBITOR OF CYP2C9 AND CYP2C19, AND MODERATE INHIBITOR OF CYP3A4! (Note: Because fluconazole has a ~30-hour half-life, even a single 150 mg tablet inhibits CYP enzymes for 4 to 7 days after ingestion!): • Sulfonylureas (Glimepiride, Gliclazide, Glipizide): Blocks CYP2C9 breakdown -> causes severe, prolonged hypoglycaemia! • Warfarin / Acitrom: Blocks CYP2C9 -> doubles PT-INR and causes major bleeding! • Phenytoin: Blocks CYP2C9/2C19 -> causes acute phenytoin ataxia/nystagmus toxicity! • Clopidogrel: Blocks CYP2C19 activation of clopidogrel! • Statins (Atorvastatin, Simvastatin): Increases myopathy/rhabdomyolysis risk
  • • QT-Prolonging Drugs: Additive arrhythmia risk with Domperidone, Ondansetron, Amiodarone, Levofloxacin, and Escitalopram
  • • Losartan: Blocks CYP2C9 conversion of losartan to its active antihypertensive metabolite

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Verify the exact dosing schedule on the prescription (Single 1-tablet pack vs. Once-Weekly vs. Daily)—patients frequently mistake a 4-tablet weekly fungal strip for a 4-day daily course! Warn diabetic patients taking Dapagliflozin/Empagliflozin + Glimepiride (who frequently get genital fungal infections and are prescribed a 150 mg Fluconazole tablet) that Fluconazole can cause their Glimepiride to trigger low blood sugar over the next 3–5 days!
  • Meal & Clock Timing Instruction: With or without food (unlike itraconazole capsules [which require food and gastric acid] or voriconazole [which requires an empty stomach], fluconazole is >90% water-soluble and absorbed completely regardless of food or PPIs!). (Any consistent time of day.)
  • Missed Dose Protocol: If on once-weekly dosing and remembered within 1–2 days, take it; if on daily dosing, take as soon as remembered unless near next dose.
  • Geriatric Dispensing Pearl: In elderly CGHS patients on Warfarin, Phenytoin, or Sulfonylureas, even a single 150 mg or weekly Fluconazole tablet can trigger dangerous toxicity—prefer topical antifungal creams (Clotrimazole/Luliconazole) for localised skin or genital candidiasis whenever possible!

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated / Dispersible Tablets & Capsules: 50 mg, 150 mg, 200 mg, 400 mg; IV Infusion: 200 mg/100 mL; Ophthalmic Drops: 0.3% w/v

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.13] (p. 99)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.